Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension of Study TKT028 with Replagal in Adult Fabry Disease Patients
2009-015985-75Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2009
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Primary endpoint: Change in left ventricular mass index (LVM/h) at Week 53. Started Nov 2009; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2009-015985-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015985-75.